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Abstract
Objective
To compare the cost-effectiveness of bladder ultrasonography, clinical history, and urody-
namic testing in guiding treatment decisions in a secondary care setting for women failing
first line conservative treatment for overactive bladder or urgency-predominant mixed uri-
nary incontinence.
Design
Model-based economic evaluation from a UK National Health Service (NHS) perspective
using data from the Bladder Ultrasound Study (BUS) and secondary sources.
Methods
Cost-effectiveness analysis using a decision tree and a 5-year time horizon based on the
outcomes of cost per woman successfully treated and cost per Quality-Adjusted Life-Year
(QALY). Deterministic and probabilistic sensitivity analyses, and a value of information anal-
ysis are also undertaken.
Results
Bladder ultrasonography is more costly and less effective test-treat strategy than clinical
history and urodynamics. Treatment on the basis of clinical history alone has an incremental
cost-effectiveness ratio (ICER) of £491,100 per woman successfully treated and an ICER of
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£60,200 per QALY compared with the treatment of all women on the basis of urodynamics.
Restricting the use of urodynamics to women with a clinical history of mixed urinary inconti-
nence only is the optimal test-treat strategy on cost-effectiveness grounds with ICERs of
£19,500 per woman successfully treated and £12,700 per QALY compared with the treat-
ment of all women based upon urodynamics. Conclusions remained robust to sensitivity
analyses, but subject to large uncertainties.
Conclusions
Treatment based upon urodynamics can be seen as a cost-effective strategy, and particu-
larly when targeted at women with clinical history of mixed urinary incontinence only. Fur-
ther research is needed to resolve current decision uncertainty.
Introduction
Lower urinary tract symptoms involving urgency or urinary incontinence are prevalent in
approximately 20% of the population world-wide [1]. Urinary incontinence is the involuntary
leakage of urine, and is classified into urge incontinence, stress incontinence (e.g. with sneezing
or coughing), or mixed incontinence—when it is both urge- and stress-related. Overactive
bladder is a syndrome characterised by urinary urgency, with or without urge incontinence,
and often frequency and nocturia [2]. The prevalence of overactive bladder is estimated in the
region of 12–17% of the population [3, 4]. Evidence, however, suggests that it remains a highly
underdiagnosed and undertreated syndrome [5]. The cost implications associated with these
urinary syndromes and their impact on quality of life have been well documented [6–10].
The uncertainty around the correct diagnosis among syndromes sharing common symp-
tomatology has established urodynamic testing as the gold-standard test when first line conser-
vative treatments have been unsuccessful. Urodynamics provides a pathophysiological
explanation of symptoms [11], and lasts approximately 30 minutes. It can identify detrusor
overactivity (DO), which commonly is the underlying pathology behind overactive bladder
symptoms, or provide alternative diagnoses including urodynamic stress incontinence, mixed
incontinence, voiding dysfunction, low compliance, or normal bladder physiology. However,
comprehensive evidence on the accuracy of urodynamics is lacking, and its role in determining
patient outcomes is increasingly questioned. For patients with uncomplicated stress inconti-
nence, evidence suggests that urodynamics is neither necessary nor cost-effective [12–14]. For
patients with overactive bladder, clinical evidence is contradictory. While there are studies con-
cluding that urodynamics is required, as symptoms tend to be an unreliable indicator of DO
[15, 16], there are also studies concluding that an urodynamic observation of DO is not a good
predictor of the outcome of a number of different treatments [17].
Current guidelines on urinary incontinence recommend conservative management of uri-
nary symptoms as a first line treatment, and the use of urodynamics only prior to more inva-
sive interventions in a secondary care setting [18]. Nevertheless, robust evidence for the use of
urodynamics in this context is lacking. The National Institute for Health and Care Excellence
(NICE) in the UK has encouraged further investigation into the role of bladder ultrasonogra-
phy to measure bladder wall thickness, which, if sufficiently accurate, offers a less invasive and
potentially cheaper alternative to urodynamics [19]. The objective of the model-based eco-
nomic evaluation is to compare the relative cost-effectiveness of basing treatment decisions on
bladder ultrasonography, clinical history, or urodynamics in women with persistent symptoms
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of overactive bladder or urge-predominant mixed incontinence for whom first line conserva-
tive treatments were not effective.
Methods
This study reports an economic evaluation carried out alongside the Bladder Ultrasound Study
(BUS), the largest cross-sectional study undertaken to estimate the accuracy of ultrasound
measurement of bladder wall thickness (BWT) in the diagnosis of DO. Details of the accuracy
study are reported in the full Health Technology Assessment (HTA) report [20]. In brief,
687 women with symptoms of overactive bladder or urgency-predominant mixed incontinence
were recruited across 22 hospitals in the UK. To be included in the study, women had to
have urinary frequency of 9 voids for at least one day in a 3 day bladder diary, mild to
severe urgency recorded on at 2 occasions in the bladder diary, and post void residual
volume< 100 ml on the bladder scan to rule out voiding dysfunction. Women with symptoms
of pure stress urinary incontinence or stress-predominant mixed incontinence, current preg-
nancy or up to six weeks postpartum, stress incontinence-related surgery and/or intradetrusor
Botulinum toxin A in the past six months, positive urine dipstick for leucocytes or nitrites, pel-
vic organ prolapse> grade II (any compartment), previous urodynamics in the past six
months, and continuous use of antimuscarinics for more than six months were excluded from
the study.
Test accuracy was determined by comparing BWTmeasurements from ultrasonography
(index test) against the results obtained from urodynamic testing (reference standard). Urody-
namic testing was carried out following the Good Urodynamic Practices Guidelines of the
International Continence Society [21]. In the BUS study, DO was defined as the occurrence of
involuntary detrusor contractions during filling cystometry that could occur spontaneously or
because of provocation [2], and filling cystometry was done with fluid filled domes and fill rate
of 100 ml/min in sitting position. Using the ultrasound, BWT was determined as the mean
measurement of the thickest part of the trigone, dome of the bladder in the midline, and the
anterior wall of the bladder. Sensitivity, specificity and predictive values for ultrasonography
were calculated using a BWT threshold of 5 mm for the diagnosis of DO [22]. All women
provided written informed consent and ethical approval was granted from the Nottingham
Research Ethics Committee (Reference: 10/H0408/57). Given the objective of the economic
evaluation, the analysis relied on data for women who had been taking conservative treatments
before enrolling into the study and had complete accuracy data (n = 209), in line with NICE
clinical recommendations [18].
Model structure
For the purpose of maintaining patient history, and given the short-term nature of the decision
problem, a decision tree was used to describe the alternative diagnostic options being compared
and the treatment pathways determined upon their diagnosis. The model was developed in
TreeAge Pro 2014 software (TreeAge Software, Inc., Williamstown, MA, USA) and concerned
women with unsuccessful first line conservative treatment. Women in the model would require
invasive interventions determined by the findings of urodynamics, bladder ultrasonography,
and clinical history. Alternative second line treatment options for each diagnostic finding were
modelled based on clinical input and NICE’s guidelines on the management of urinary inconti-
nence [23].
In this study, two different model structures were explored. In the first structure, the three
test-treat strategies were directly compared assuming that clinical history plays no role in deter-
mining the need for urodynamics or ultrasound, or in influencing treatment options in cases of
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disagreement. The second structure, allows for these diagnostic tests to depend upon the out-
come of clinical history.
Urodynamic testing provides diagnoses of overactive bladder, urodynamic stress and mixed
incontinence, normal bladder physiology, low compliance, and voiding dysfunction. For over-
active bladder, treatment with either botulinum toxin injections or a neurostimulation (percu-
taneous tibial nerve) was modelled, depending on patient and physician preferences. For
women remaining symptomatic, a peripheral nerve evaluation was assumed to follow in order
to assess whether a permanent implantation of a neurostimulator device would be successful,
or women would require further botulinum toxin injections or neurostimulation, depending
on which of the two interventions had not been carried out earlier in the model (Fig 1). For
stress incontinence, initial treatment in the model involved a sling surgery followed by a Burch
colposuspension if women remained symptomatic, unless treatment for overactive bladder had
previously been given. For the treatment of mixed incontinence, a sling surgery and Burch col-
posuspension were also assumed to take place with the exception that, due to the presence of
urinary urgency, women had the option of botulinum toxin injections prior to sling surgery.
Women with urodynamic findings of normal bladder physiology, low compliance only, or
voiding dysfunction only were assumed to remain symptomatic without further invasive
interventions.
Treatment pathways following bladder ultrasonography and clinical history are similar, but
reflect variations arising from the fact that for both strategies, treatment for either overactive
bladder or mixed urinary incontinence can only be initiated given the urgency-predominant
symptoms of the population modelled (S1 and S2 Figs). The primary study assessed the accu-
racy of bladder ultrasonography for diagnosing DO using a predefined threshold of BWT
(5mm) on the basis of previous research [22]. This was followed in the model using accuracy
data from the primary study [20]. When BWT is below this threshold, the ultrasound cannot
distinguish between alternative urinary syndromes and treatment for mixed incontinence was
Fig 1. Decision sub-tree representing the treatment pathway of women with an urodynamic diagnosis of detrusor overactivity
[The + sign denotes similar model structure].
doi:10.1371/journal.pone.0160351.g001
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assumed to be initiated. For clinical history, the criterion of whether women only had urinary
urgency, with or without urge incontinence, or had urgency-predominant mixed incontinence
was used to indicate diagnoses either of overactive bladder or of mixed incontinence. A more
detailed graphical representation of the decision model is provided in the HTA report [20].
Additional model assumptions
For the purposes of the analysis some further assumptions were required:
• Treatment with botulinum toxin may result in voiding dysfunction [24].
• Women with voiding dysfunction would require self-catheterisation training [25].
• Repeated botulinum toxin injections, commonly provided at yearly intervals, have shown to
be clinically effective [26, 27]. It was assumed that women could have up to 3 injections.
• Neurostimulation was offered in 12 sessions, a week apart over the first 3 months [28]. If it
was clinically effective, a monthly maintenance session would be needed thereafter [29].
• After an implantation of a neurostimulator device, a revision of the surgery, maintenance or
removal of the neurostimulator may be needed [30, 31]. These were assumed to take place at
the end of the model’s time horizon.
• A maximum of two diagnostic tests were assumed to be carried out, one when entering the
model, and another if women remained symptomatic.
• If a woman became subjectively cured, improvements were assumed to last throughout the
model’s time horizon.
Probabilities
Probabilities for symptoms’ prevalence and test accuracy were taken from the primary study
(S1 and S2 Tables) [20]. The probability of a woman becoming subjectively cured by a given
intervention and subject to the stated underlying condition, and other probabilities used in the
model were drawn from secondary sources [24, 26, 28, 30–37]. These are shown in Table 1.
Probabilities applying to rare circumstances, such as in cases of misdiagnosis, were not all
available in published sources, and values were, therefore, elicited independently from the
expert opinion of eight study collaborators on the 18th of June 2014 (Table 1). In the absence of
relevant information, expert opinion is considered a legitimate source of information in deci-
sion-analytic modelling [38]. Since these probabilities are not commonly encountered, it was
considered appropriate to decide a priori the use of a beta distribution and a simple elicitation
approach, asking for most likely value as well as lowest and highest, and interpreting these as
mean and 95% confidence intervals (CIs). Use of more elaborate elicitation techniques [39]
was not expected to have an appreciable impact on the modelling.
Costs
Cost data were drawn from national sources (Table 2) [40, 41], and calculated in 2012–2013
UK pounds (£). Unit costs adopted from the NHS Reference Costs (2012–13) [40] were calcu-
lated based on the weighted average value of elective inpatient and day-case costs and the pro-
portion of patients in each type of care. Unit costs from the “Urology” category were selected
instead of the average across different medical specialties, apart from the case of the bladder
ultrasonography for which a total Healthcare Resource Groups (HRG) cost was only available.
Managing Urinary Symptoms: Economic Evaluation
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The cost of three botulinum toxin injections was calculated by multiplying the unit cost of each
injection (£912; 95% CIs: £704–£1,060) by the proportion of women undergoing each
injection.
Outcomes
The primary outcome was “women successfully treated”, determined by subjective cure. The
secondary outcome was “quality-adjusted life-years (QALYs)”, which is the recommended out-
come for economic evaluations in the UK [42], and combines quantity with quality of life mea-
sured using preference weights. Quality of life data for women entering the model were taken
Table 1. Effectiveness data and other model parameters.
Parameter Base-case value₊ (95%
CIs)
Distribution (parameter
values)‡
References
Probability of subjective cure*
Botulinum toxin—Detrusor overactivity† 0.568 (0.464, 0.669)ǂ Beta (50, 38) Dowson et al [26]
Botulinum toxin—Mixed incontinence 0.329 (0.200, 0.483) Beta (13.42, 27.36) Expert opinion
Botulinum toxin—Stress incontinence 0.143 (0.133, 0.375)§ Beta (4.32, 25.86) Expert opinion
Neurostimulation—Detrusor overactivity 0.606 (0.558, 0.653)ǂ Beta (245, 159) Burton et al [28]
Neurostimulation—Stress/mixed incontinence 0.314 (0.283, 0.567) Beta (12.36, 27) Expert opinion
Implanted neurostimulator—Detrusor overactivity 0.675 (0.633, 0.715)ǂ Beta (338, 163) Brazzelli et al [30]
Implanted neurostimulator—Stress/mixed incontinence 0.271 (0.233, 0.550) Beta (7.74, 20.82) Expert opinion
Sling surgery—Detrusor overactivity 0.310 (0.250, 0.350) Beta (5.84, 13) Weber and Walters [37]
Sling surgery—Stress incontinence 0.868 (0.841, 0.894)ǂ Beta (547, 83) Latthe et al [32]
Sling surgery—Mixed incontinence 0.560 (0.534, 0.579)ǂ Beta (1050, 837) Jain et al [33]
Colposuspension—Detrusor overactivity 0.163 (0.153, 0.386) Beta (5.95, 30.56) Expert opinion
Colposuspension—Stress incontinence 0.690 (0.612, 0.762)ǂ Beta (100, 45) Dean et al [35]
Colposuspension—Mixed incontinence 0.489 (0.381, 0.595)ǂ Beta (40, 42) Kulseng‐Hanssen et al
[36]
Other probabilities
Choose botulinum toxin prior to sling surgery 0.314 (0.275, 0.683) Beta (5.74, 12.53) Expert opinion
Choose botulinum toxin over neurostimulation 0.750 (0.421, 0.963)ǂ Beta (6, 2) Expert opinion
Voiding difﬁculties due to botulinum toxin 0.086 (0.042, 0.143)ǂ Beta (10, 106) Tincello et al [24]
Require implantation of neurostimulator—Detrusor
overactivity
0.670 (0.450, 0.880) Beta (11.23, 5.53) Brazzelli et al [30]
Neurostimulator requires revision < 2 years 0.090 (0.064, 0.119)ǂ Beta (36, 366) Siddiqui et al [31]
Neurostimulator requires revision 2 years 0.330 (0.299, 0.362)ǂ Beta (282, 573) Brazzelli et al [30]
Neurostimulator requires maintenance 2 years 0.150 (0.111, 0.195ǂ Beta (42, 237) Brazzelli et al [30]
Neurostimulator requires removal 0.107 (0.068, 0.152ǂǂ Beta (22, 184) Siddiqui et al [31]
*The ﬁgures are probabilities that the patient will be subjectively cured by the given intervention subject to the stated underlying condition. These are given
as point estimates with 95% conﬁdence intervals and corresponding beta distributions.
₊ Mean value of a model parameter that was used in main analysis.
† The value was estimated using the disaggregated contribution of each of the three injections (34%, 52%, and 14%) and the subsequent drop-out rates
(20%, 8%, and 0%) [26]. The disaggregated contribution and drop-out rates were assumed to be the same across syndromes.
ǂ Information in the source consisted of point estimates of effectively treated number of patients, and 95% conﬁdence intervals (CIs) have been derived from
this information.
‡Where mean and number of patients effectively treated was available, these were used to derive distribution parameters. In other cases, distributions were
ﬁtted to the mean and 95% conﬁdence intervals (CIs).
§ This value represents the most conservative estimate of effectiveness in case of misdiagnosis and was used as a proxy of effectiveness in cases where
women with low compliance only, voiding dysfunction only, or normal bladder received interventions as a result of misdiagnosis.
doi:10.1371/journal.pone.0160351.t001
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from the primary study (Table 3) [20]. To identify quality of life data for outcomes experienced
during the modelled time horizon, a review of the Cost-Effectiveness Analysis Registry [43]
was performed using the search terms “overactive bladder”, “urinary incontinence”, and “detru-
sor overactivity”. Eighteen studies were identified and preference weights from one study were
selected to represent the quality of life of women subjectively cured, with and without side-
effects [44]. This study was selected because values were obtained using the time trade-off
method, which has sound theoretical underpinnings in utility theory, and were relevant to the
symptoms and type of interventions modelled [45]. In the absence of other estimates, women
remaining symptomatic were assumed to retain their initial quality of life, which is a common
assumption in cost-effectiveness analyses in this clinical context [44, 46–48]. QALYs were esti-
mated by combining the utility weights with estimates of duration of the different health states.
Analyses
Two separate economic analyses were carried out from the perspective of the UK National
Health Service (NHS) and results were presented in incremental cost-effectiveness ratios
Table 2. Unit cost data (£, 2012–13 price base).
Intervention HRG code* Base-case value (95% CIs)₊ Distribution (parameter values)‡ References
Urodynamics LB42A 401 (216–462) Gamma (40.65, 9.86) NHS Reference Cost [40]
Bladder ultrasonography RA23Z† 51 Gamma (1.00, 51.07) Ibid.
Botulinum toxin injection LB14Z 912 (704–1,060) Gamma (100.67, 9.06) Ibid.
Neurostimulation AA21F 2,221 (1,274–2,838) Gamma (30.81, 72.08) Ibid.
Sling surgery LB59Z 3,917 (2,599–5,309) Gamma (31.93, 122.69) Ibid.
Peripheral nerve evaluationǂ AA21F 1,162 (1,010–1,293) Gamma (258.88, 4.49) Ibid.
Implantation of neurostimulator AB07Z 6,530 (4,966–8,347) Gamma (57.14, 114.28) Ibid.
Removal/ maintenance of neurostimulator AB04Z 4,160 (2,960–5,831) Gamma (32.09, 129.65) Ibid.
Burch colposuspension LB59Z 3,917 (2,599–5,309) Gamma (31.93, 122.69) Ibid.
Self-catheterisation training§ 84 Gamma (1.00, 84.00) Curtis [41]
* Based on urology category unless otherwise indicated.
₊ Mean value of a model parameter that was used in main analysis.
† Based on total Health Resource Groups (HRG).
ǂ As a day case.
‡ Distributions were ﬁtted based on mean value and 95% conﬁdence intervals (CIs) apart from the cases of bladder ultrasonography and self-catheterisation
training, where distributions were ﬁtted by the method of moments assuming a variance equal to the mean cost.
§ Assuming an hour contact with a nurse.
doi:10.1371/journal.pone.0160351.t002
Table 3. Quality of life data.
Description Base-case value (95% CIs)₊ Distribution (parameter values)‡ References
Detrusor overactivity 0.600 (0.532–0.668) Beta (8.96, 5.98) BUS study [20]
Stress urinary incontinence 0.660 (0.514–0.807) Beta (18.92, 9.75) Ibid.
Mixed urinary incontinence 0.718 (0.637–0.799) Beta (49.12, 19.29) Ibid.
Normal bladder 0.656 (0.558–0.753) Beta (22.13, 11.61) Ibid.
Low compliance or voiding dysfunction 0.744 (0.547–0.942) Beta (11.76, 4.05) Ibid.
Subjective cure without side effects 0.920 (0.710–0.990) Beta (10.69, 0.93) Chen et al [44]
Subjective cure with side effects 0.870 (0.830–0.900) Beta (304, 45.43) Ibid.
₊ Mean value of a model parameter that was used in main analysis.
‡ Distributions were ﬁtted based on mean value and 95% conﬁdence intervals (CIs).
doi:10.1371/journal.pone.0160351.t003
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(ICERs). The first analysis assessed the cost-effectiveness of basing treatment decision upon
bladder ultrasonography and clinical history alone compared with the treatment based upon
the gold-standard urodynamics. The second analysis additionally explored all the different
ways in which clinical history and a diagnostic test could be used together. This aimed to assess
whether a diagnostic test would be more cost-effective when offered in a selective sub-group of
women (i.e. those with clinical history of overactive bladder only or those with a clinical history
of mixed incontinence only). A 5-year time-horizon was considered appropriate to reflect key
differences in terms of costs and benefits for the test-treat strategies compared. Costs and
QALYs accruing beyond 12 months were discounted at an annual rate of 3.5% [42].
A number of sensitivity analyses were performed. Univariate analyses explored the impact
of: (a) reducing the cost of urodynamics from £401 (95% CIs: £216–£462) to £173, which rep-
resents the weighted average value of total HRGs [40]; (b) doubling the cost of sling surgery to
account for possible adverse events [32]; and (c) lowering the utility weight of women subjec-
tively cured from 0.92 to 0.84, which represents the mean EQ-5D index score for women who
reported low symptoms bother in the primary study [20]. Multivariate analyses explored the
impact of: (a) lowering the accuracy of urodynamics [13], while improving the accuracy of clin-
ical history by complementing it with urinary diaries [49]; (b) placing the rates of effectiveness
elicited from expert opinion to the lowest and highest value; and (d) assuming one diagnostic
test is only performed when entering the model.
For a more comprehensive representation of parameter uncertainty, a probabilistic sensitiv-
ity analysis (PSA) was undertaken. Using a Monte Carlo simulation, 10,000 iterations of the
model were performed by repeated random draws from probability distributions attached to
model parameters. Beta and Dirichlet distributions were used for binomial and multinomial
data respectively, and a Gamma distribution for costs [50]. The results from all model itera-
tions were averaged, and at any given level of decision-makers’ willingness-to-pay (WTP) per
additional unit of outcome the optimal strategy was determined from the average results. To
present the proportion of model iterations that favoured the overall optimal test-treat strategy
at each threshold of WTP, cost-effectiveness acceptability frontiers (CEAFs) were used [51].
CEAFs plot the probability of the optimal strategy being cost-effective, under current uncer-
tainty, at different WTP values per additional unit of outcome.
Given that decision uncertainty may lead to sub-optimal policy recommendations, the
opportunity cost of gaining further information to assist decision-making in the future needs
to be evaluated. A metric which indicates whether undertaking further research is potentially
more worthwhile than adopting a decision under current uncertainty is the expected value of
perfect information (EVPI). The EVPI represents the maximum monetary value that rational
decision-makers would be willing to spend for gaining more information at each threshold of
WTP per additional unit of outcome, and combines the probability of a wrong decision with
the monetary value of the gain that would be expected in changing the decision from the
wrong to the correct one [50, 52, 53]. For example, if the cost of further research, such as a ran-
domised controlled trial, is lower than the EVPI then investing on further research is poten-
tially more worthwhile. The EVPI was estimated at a population level based on estimates of
incidence (54,000) [3, 4, 54, 55], and the number of years that research was assumed to be use-
ful (10 years) with 3.5% annual discount rate.
Results
In the first analysis, a test-treat strategy based upon bladder ultrasonography was dominated
by the strategies of urodynamics and clinical history, as it was more expensive and less effective
for both outcomes of the analysis. As shown in Table 4, treatment based upon clinical history
Managing Urinary Symptoms: Economic Evaluation
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led to an additional 26 cases per 10,000 women successfully treated compared with treatment
based upon urodynamics at an additional cost of £1,278 per woman, and the corresponding
ICER was £491,100 per woman successfully treated.
The CEAF in Fig 2 shows that the probability of the urodynamics test-treat strategy being
cost-effective exceeded 61% for any value of WTP below £100,000 per additional woman suc-
cessfully treated. In terms of QALYs, treatment based upon clinical history resulted in an addi-
tional 0.021 QALYs gained per woman compared with treatment based upon urodynamics.
Given the additional cost of £1,278 per woman, the mean ICER for the clinical history strategy
compared with urodynamics was estimated at £60,200 per QALY. The results of the PSA show
that urodynamics was likely to be the optimal test-treat strategy with 72% probability of being
cost-effective at the conventional threshold of £20,000 per QALY (Fig 3) [56].
The results of the second analysis showed that, in comparison to the treatment of all women
on the basis of urodynamics, restricting the use of urodynamics to women with clinical history
of mixed urinary incontinence led to an additional 309 successfully treated women per 10,000
at an additional cost of £603 per woman (Table 4). This resulted in an ICER of £19,500 per
woman successfully treated. Treating these women on the basis of bladder ultrasonography
required an additional £641 per woman and led to an additional 82 cases per 10,000 women
successfully treated compared with the use of urodynamics in the same women, which gave an
ICER of £78,600 per additional woman successfully treated. In the absence of a pre-specified
threshold of WTP per additional woman successfully treated, the identification of the probabil-
ity of the optimal strategy being cost-effective is less straightforward, but £28,000 could be a
theoretically acceptable threshold of WTP per woman subjectively cured [20]. At this value,
there is almost 50% probability that performing urodynamics only in women with a clinical
history of mixed incontinence is a cost-effective test-treat strategy (Fig 4).
In terms of QALYs, having urodynamics as an adjunct to clinical history in women with
patient history of mixed incontinence led to an additional 0.476 QALYs gained per woman at
an additional cost of £603 compared with the treatment of all women on the basis of urody-
namics, leading to an ICER of £12,700 per additional QALY. The results of the PSA indicated
Table 4. Table of results.
Test-treat strategy Cost Women successfully
treated
QALYs ICER per woman successfully
treated
ICER per
QALY
First analysis
Urodynamics £4,524 0.615 3.669
Clinical history £5,801 0.618 3.691 £491,100 £60,200
Bladder ultrasonography £5,947 0.615 3.621 Dominated Dominated
Second analysis
Urodynamics—All women £4,524 0.615 3.669
Urodynamics—Conditional on clinical history of mixed
incontinence
£5,126 0.646 3.717 £19,500 £12,700
Urodynamics—Conditional on clinical history of overactive
bladder
£5,198 0.587 3.643 Dominated Dominated
Bladder ultrasonography—Conditional on clinical history of
mixed incontinence
£5,768 0.654 3.689 £78,600 Dominated
Clinical history—All women £5,801 0.618 3.691 Dominated Dominated
Bladder ultrasonography—All women £5,947 0.615 3.621 Dominated Dominated
Bladder ultrasonography—Conditional on clinical history of
overactive bladder
£5,965 0.596 3.636 Dominated Dominated
QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0160351.t004
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Fig 2. Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat strategy (i.e.
urodynamics) being cost-effective across different willingness to pay thresholds per additional woman successfully treated.
doi:10.1371/journal.pone.0160351.g002
Fig 3. Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat
strategy being cost-effective across different willingness to pay thresholds per additional quality-adjusted
life-year (QALY).
doi:10.1371/journal.pone.0160351.g003
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that, under current uncertainty, treating only in women with clinical history of mixed inconti-
nence based upon urodynamics, with the rest being treated based upon clinical history, was
likely to be the optimal test-treat strategy with 76% probability of being cost-effective at the
commonly cited threshold of £20,000 per QALY (Fig 5). Conclusions drawn from both
Fig 4. Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat
strategy being cost-effective across different willingness to pay thresholds per additional woman
successfully treated.
doi:10.1371/journal.pone.0160351.g004
Fig 5. Cost-effectiveness acceptability frontier (CEAF) indicating the probability of the optimal test-treat
strategy being cost-effective across different willingness to pay thresholds per additional quality-adjusted
life-year (QALY).
doi:10.1371/journal.pone.0160351.g005
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analyses remained robust to all sensitivity analyses except for the scenario where the highest
effectiveness rates elicited from expert opinion were assumed in all cases of misdiagnosis (S3
Table).
Figs 6 and 7 show the population expected value of perfect information (EVPI) for both out-
comes (i.e. women successfully treated and QALYs) of the two analyses undertaken across a
range of WTP values for an additional unit of outcome. For the thresholds of £28,000 per
woman successfully treated and £20,000 per QALY, population EVPI was found to be £36 mil-
lion and £98 million respectively for the first analysis, and £77 million and £40 million for the
second analysis. The large population EVPI indicates that further research for reducing current
decision uncertainty is worthwhile.
Discussion
Main findings
This model-based economic evaluation suggested that urodynamics is a cost-effective compo-
nent in the treatment of women failing first line conservative treatments. The first analysis
showed that whilst treating on the basis of clinical history resulted in slightly more cases of
women successfully treated and QALYs over the modelled time period compared with urody-
namics, treating on the basis of urodynamics led to a worthwhile saving in cost achieved by the
lower levels of unnecessary and expensive treatment. The second analysis explored whether
urodynamic testing of a sub-group of women would provide a more efficient use of public
health care resources. The analysis concluded that the more cost-effective test-treat strategy
was to treat women with clinical history of overactive bladder without diagnostic testing and to
undertake urodynamics in women with clinical history of mixed urinary incontinence. For
both analyses, decisions remained robust to extensive sensitivity analysis concerning the model
assumptions but subject to large uncertainties relating to the data inputs, which, as shown in
the value-of-information analysis, indicate that further primary research is required.
Fig 6. Population expected value of perfect information (EVPI) for the two outcomes of first analysis.
doi:10.1371/journal.pone.0160351.g006
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Strengths and limitations
To the best of our knowledge, this is the first study attempting to compare the cost-effective-
ness of urodynamics, bladder ultrasonography, and clinical history as test-treat strategies for
women with symptoms of overactive bladder or urgency-predominant mixed incontinence
referred to a secondary care setting. The study benefited from prevalence and accuracy data
directly estimated from the BUS study. Costs were informed from national sources, and the
main clinical pathways were parameterised with data mostly from meta-analyses and system-
atic reviews, and based on national treatment guidelines. These are likely to have extended the
generalisability of the study’s findings beyond the UK setting. Finally, all assumptions used in
the model were agreed in advance and key assumptions were tested in sensitivity analyses.
There are, however, a number of limitations. The results of the economic evaluation may
overstate the cost-effectiveness of urodynamic testing. On one hand, this is because urinary
diaries complement clinical history in practice, and thus providing a joint decision based upon
clinical assessment rather than patient history alone. On the other hand, ambulatory urody-
namics may be more sensitive in detecting DO [57], and other diagnoses [58, 59], than conven-
tional laboratory urodynamics. An attempt to explore the cost-effectiveness of the different
strategies in light of this evidence was undertaken in a sensitivity analysis. Furthermore, in the
absence of available estimates of clinical effectiveness in cases of misdiagnosis, values were elic-
ited from expert opinion. Deterministic and probabilistic sensitivity analyses were undertaken
to account for the uncertainty around these estimates. Another limitation is that symptoms of
urinary incontinence are commonly associated with profound personal costs. Therefore, eco-
nomic analyses from a societal perspective may provide further insight into the cost-effective-
ness of the test-treat strategies modelled.
Fig 7. Population expected value of perfect information (EVPI) for the two outcomes of second analysis
[The “spikes” in the figure correspond to the points where decision changes, namely to the ICER of the
test-treat strategy “Urodynamics for women with clinical history of mixed incontinence” compared with
“Urodynamics for all women”, which was £19,500 per woman successfully treated and £12,700 per QALY].
doi:10.1371/journal.pone.0160351.g007
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An additional limitation relates to the quality of life data used in the model. In the absence
of robust utility weights, it was assumed that women remaining symptomatic would maintain
their initial quality of life, or that they would have a utility score of 0.92 if they became subjec-
tively cured, with the impact of an alternative utility score being explored in a sensitivity analy-
sis. In reality, however, utility decrements can occur after invasive interventions, and utility
gains may differ among different urinary syndromes or severity of symptoms. This lack of evi-
dence is potentially attributable to the common use of disease-specific outcome measures,
which offer limited usefulness as outcome measures in cost-effectiveness analyses [60],
although mapping algorithms have now started to be developed [61]. Nevertheless, lower uri-
nary tract symptoms are likely to be associated with significant non-health impacts (e.g. embar-
rassment) and instruments capturing wider wellbeing benefits, such as the ICECAP measures,
may offer a more relevant evaluative framework for treatment outcomes [62].
Finally, although the model’s time horizon is long enough to capture important costs and
outcomes associated with the different test-treat strategies, the assumption that subjective
improvements will last for the modelled period may not be completely valid in all instances.
For example, tachyphylaxis to neurostimulation is not well known over time. It is better studied
in botulinum toxin injections where there is a known tachyphylaxis rate with repeated injec-
tions, although this is small. Such variations from the model assumption, however, were not
expected to have a significant impact on the study’s findings.
Interpretation
Based on the decision model used and the limitations discussed, the results of the first analysis
indicated that determining second line invasive interventions in women with persistent symp-
toms of overactive bladder or urgency-predominant mixed incontinence on the basis of urody-
namics is the optimal strategy. This finding supports the conclusions of other studies in favour
of urodynamic testing [15, 16]. These studies, however, are all underpinned by the premise that
effective treatment for overactive bladder symptoms is only determined through a successful
identification of DO, symptom which explains a part of overactive bladder syndrome, and
which can only be identified urodynamically. This study also used urodynamics as a gold-stan-
dard test, and this is a potential limitation because its accuracy is still open to debate.
An increasing number of studies conclude that an urodynamic identification of DO does
not predetermine the clinical effectiveness of a number of different interventions for women
with overactive bladder [17, 63–65]. These findings are aligned to the conclusions drawn from
the second analysis, which indicated that the most cost-effective test-treat strategy is to carry
out urodynamic testing only in women with a clinical history of mixed urinary incontinence.
Restricting the use of urodynamics to these women seems to be further supported from evi-
dence pointing out that mixed urinary symptoms are more commonly encountered than
mixed conditions [66], which result in a large proportion of women reporting symptoms of
mixed urinary incontinence in clinical history [67]. The order of magnitude of this figure
appears to be around 50% [66], which is similar to what was found in the BUS study (52%)
[20].
Conclusion
The findings of this paper indicate that restricting the use of urodynamics to women with
patient history of mixed urinary incontinence only is potentially the more cost-effective way
forward for guiding second line treatment decisions. Further research is, however, needed to
reduce the expected opportunity loss associated with the decision of moving away from current
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practice of basing invasive treatments for all women failing first line conservative treatments
on urodynamic findings.
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